about
Therapeutical approaches in melasma.A rational approach to the treatment of vitiligo and other hypomelanoses.New and experimental treatments of vitiligo and other hypomelanoses.Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair.In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopyA study of fractional CO₂ laser resurfacing: the best fluences through a clinical, histological, and ultrastructural evaluation.Induction of apoptosis by fractional CO2 laser treatment.Gottron papules: a pathognomonic sign of dermatomyositis.Prurigo nodularis and lichen simplex chronicus.Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsDetection and management of latent tuberculosis infections before biologic therapy for psoriasis.An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17.Tuberculosis reactivation risk in dermatology.Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis.PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm.SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survivalGuidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.Measuring psoriatic disease in clinical practice. An expert opinion position paper.Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis.Stem cell factor affects tumour progression markers in metastatic melanoma cells.Why is Kikuchi-Fujimoto disease misleading?Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis.Sequential effects of photodynamic treatment of basal cell carcinoma.Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients.Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic?Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment.High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma.Etanercept therapy in a hepatitis B virus (HBV)-positive psoriatic patient developing a monoclonal gammopathy of undetermined significance.Epidermal barrier reaction to an in vitro psoriatic microenvironment.Fissured tongue responding to biologics during the treatment of psoriasis: the importance of detecting oral involvement of psoriasis.Protease-activated receptor-2 downregulation is associated to vitiligo lesions.Clinical experience with infliximab biosimilar in psoriasis.Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus.Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment.Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?Cutaneous hyperpigmentation induced by apremilast.
P50
Q30832982-E90F1B11-DFCA-4C38-AFED-7CE621E5EA14Q33292357-D851D319-CBC6-4B11-A57A-B17BA9088434Q33292361-B366D3AD-9193-44DC-BC12-A29463010E73Q33515121-9D692ABC-7B6F-44B6-A00F-85D701B75EF8Q33915866-D7628031-F553-4538-BE18-A8AAB4168B22Q34012266-E6F3FABE-37AA-46DB-9E1B-57EA16B5A25FQ34443788-4F3DDC8F-724A-41D6-A483-F5908FAF73C3Q36586218-C8576F1D-CFB0-4DC1-B3E9-8712F0D0B5E6Q37101740-47A7EB79-D450-4AAC-ABB8-40B23C37FF19Q37412095-032B2744-0FDF-4BF3-820A-45CB36FF26F0Q37972320-D3825BF8-291B-406A-BCB9-2E3817701708Q38208578-44A1B42A-CF18-48E5-A68A-C8EB54763AFAQ38208741-09AEC12C-DE89-4604-83B3-B967D6391A63Q38208743-1DDFB0D4-D1A9-4EC8-97D9-CAEE218195D4Q38239127-0633130B-540B-4C90-8598-D2E19BFA4E3BQ38265056-0033960A-B53F-411C-B373-C1712BC30DE3Q38281761-6B888EB6-E185-47BB-881D-10F8FD292CE9Q38330893-9A5F80EC-3627-4863-A40E-C867E893B6EDQ38508340-3872C623-D749-44B3-A77B-6E85EC600690Q39104136-DA9AA9F4-16BD-4145-897F-D30200EA2A06Q40222370-B62C0670-783B-4FD2-A7D3-3E6D59BC1563Q40307480-CEEF5E5E-D178-49A4-9425-C5241B582492Q41545261-3A592D44-E84A-4B48-8304-2AA55520A62EQ42450724-7E808C3A-67D2-45FC-8D13-D201A33C30ACQ42671939-2ADB62E3-EFF7-4AA4-99FC-74229B4634EDQ43171356-5F8EC711-FF87-4AA5-B8D7-FECF64F60553Q43461744-28FA56FA-7D73-450F-ABA7-704A2F09C1AAQ44104600-E770E80E-F384-4D3A-AABD-578E23BF8FAAQ44126420-6A2C1B0C-9B5E-460D-8383-EB41A3593D06Q44148230-DA6601E0-133F-4E6F-B91A-C835A95DE23FQ45073477-D07A7D93-3915-4DC3-AC9D-87491D5D6BB5Q45364783-D9379C15-31B0-4EB8-BBA1-612B0B4CBAC4Q47826010-B9207FE9-8415-4994-AB55-5134752CA023Q47860352-B42B75C0-6753-4309-A4D8-8D501E46AA43Q48004573-F3678141-3EC4-46E0-B2A4-9490648D5EC0Q48227028-8542FED0-0010-467F-B0D2-F30CB421AEDCQ48304684-592A16FA-4654-4121-94D8-CD86FDB80E1EQ48306736-142A82C0-9810-4E0F-AA6B-A13BDD8E5989Q49815749-7B6C5110-BF62-4AD6-8896-43967B69AAB1Q49923785-E5891628-E5EC-4FF5-9287-6D7622C7F87C
P50
description
researcher ORCID ID = 0000-0002-5997-2045
@en
wetenschapper
@nl
name
Francesca Prignano
@ast
Francesca Prignano
@en
Francesca Prignano
@es
Francesca Prignano
@nl
type
label
Francesca Prignano
@ast
Francesca Prignano
@en
Francesca Prignano
@es
Francesca Prignano
@nl
prefLabel
Francesca Prignano
@ast
Francesca Prignano
@en
Francesca Prignano
@es
Francesca Prignano
@nl
P1153
35581045300
P31
P496
0000-0002-5997-2045